Boehringer Ingelheim

More data supports Jardiance lead in cardiovascular battle

September 14, 2017

Cardioprotective effect occurred in patients independently of blood sugar control

More data supports Jardiance lead in cardiovascular battle

https://pharmaphorum.com/news/bililly-produce-data-supporting-diabetes-drug-jardiance/

Boehringer to develop fibrosis treatment with Inventiva

September 5, 2017

Boehringer to progress R&D partnership that began last year

Boehringer to develop fibrosis treatment with Inventiva

https://pharmaphorum.com/news/boehringer-takes-option-develop-fibrosis-inventiva/

Galapagos and FibroGen drugs offer hope in IPF

August 15, 2017

Drugs improve on existing medicines from Boehringer and Roche.

Galapagos and FibroGen drugs offer hope in IPF

https://pharmaphorum.com/news/galapagos-fibrogen-ipf/

Daiichi Sankyo anticoagulant gains EU label boost

July 21, 2017

Label gives guidance in use when restoring normal heart rhythm

Daiichi Sankyo anticoagulant gains EU label boost

https://pharmaphorum.com/news/daiichi-sankyo-noac-get-eu-label-boost/

Boehringer looks to cancer immunotherapy combinations

April 7, 2017

BI developing combinations with its own checkpoint inhibitors

Boehringer looks to cancer immunotherapy combinations

https://pharmaphorum.com/news/boehringer-looking-cancer-immunotherapy-combos/

Boosted by new drugs, Boehringer shrugs off patent expiry

April 6, 2017

BI boosted by new diabetes and respiratory drugs.

Boosted by new drugs, Boehringer shrugs off patent expiry

https://pharmaphorum.com/news/boosted-new-drugs-boehringer-shrugs-off-patent-expiry/

Real world data will help AZ’s Farxiga in cardio battle

March 20, 2017

AZ hopes data will boost sales of its Farxiga.

Real world data will help AZ’s Farxiga in cardio battle

https://pharmaphorum.com/news/sglt-2s-cut-mortality-diabetes-az-data/

Precision medicine and data science: the ‘new normal’ for drug development

January 31, 2017

Balancing innovation and huge unmet patient need with burgeoning cost constraints.

Precision medicine and data science: the ‘new normal’ for drug development

https://pharmaphorum.com/views-and-analysis/precision-medicine-data-science-new-normal-drug-development/

Lilly/Boehringer diabetes combos get cardio data boost

January 5, 2017

Lilly/Boehringer gain further advantage in US diabetes market.

Lilly/Boehringer diabetes combos get cardio data boost

https://pharmaphorum.com/news/diabetes-lillyboehringer-data-boost/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Boehringer Ingelheim

More data supports Jardiance lead in cardiovascular battle

Boehringer to develop fibrosis treatment with Inventiva

Galapagos and FibroGen drugs offer hope in IPF

Daiichi Sankyo anticoagulant gains EU label boost

Boehringer looks to cancer immunotherapy combinations

Boosted by new drugs, Boehringer shrugs off patent expiry

Real world data will help AZ’s Farxiga in cardio battle

Precision medicine and data science: the ‘new normal’ for drug development

Lilly/Boehringer diabetes combos get cardio data boost

CDD for Biologics Summit 2017

Neoantigen Summit 2017

ICI Summit Europe 2017

6th International GMP, GCP & Quality Control Summit

Inhalation and Respiratory Drug Products Summit

3rd Annual Pre-Filled Syringes Summit

Search

Advanced Search

Trending

Boehringer Ingelheim